key: cord-0274655-1w8lywnq
authors: Wollner, Clayton J.; Richner, Michelle; Hassert, Mariah A.; Pinto, Amelia K.; Brien, James D.; Richner, Justin M.
title: A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity
date: 2021-01-06
journal: bioRxiv
DOI: 10.1101/2021.01.05.425517
sha: 8d190285b051c4c5e014da397b4b8b7ada357cee
doc_id: 274655
cord_uid: 1w8lywnq

Dengue virus (DENV) is the most common vector-borne viral disease with nearly 400 million worldwide infections each year concentrated in the tropical and subtropical regions of the world. Severe dengue complications are often associated with a secondary heterotypic infection of one of the four circulating serotypes. In this scenario, humoral immune responses targeting cross-reactive, poorly-neutralizing epitopes can lead to increased infectivity of susceptible cells via antibody-dependent enhancement (ADE). In this way, antibodies produced in response to infection or vaccination are capable of contributing to enhanced disease in subsequent infections. Currently, there are no available therapeutics to combat DENV disease, and there is an urgent need for a safe and efficacious vaccine. Here, we developed a nucleotide-modified mRNA vaccine encoding for the membrane and envelope structural proteins from DENV serotype 1 encapsulated into lipid nanoparticles (prM/E mRNA-LNP). Vaccination of mice elicited robust antiviral immune responses comparable to viral infection with high levels of neutralizing antibody titers and antiviral CD4+ and CD8+ T cells. Immunocompromised AG129 mice vaccinated with the prM/E mRNA-LNP vaccine were protected from a lethal DENV challenge. Vaccination with either a wild-type vaccine, or a vaccine with mutations in the immunodominant fusion-loop epitope, elicited equivalent humoral and cell mediated immune responses. Neutralizing antibodies elicited by the vaccine were sufficient to protect against a lethal challenge. Both vaccine constructs demonstrated serotype specific immunity with minimal serum cross-reactivity and reduced ADE compared to a live DENV1 viral infection. IMPORTANCE With 400 million worldwide infections each year, dengue is the most common vector-born viral disease. 40% of the world’s population is at risk with dengue experiencing consistent geographic spread over the years. With no therapeutics available and vaccines performing sub optimally, the need for an effective dengue vaccine is urgent. Here we develop and characterize a novel mRNA vaccine encoding for the dengue serotype 1 envelope and premembrane structural proteins that is delivered via a lipid nanoparticle. Our DENV1 prM/E mRNA-LNP vaccine induces neutralizing antibody and cellular immune responses in immunocompetent mice and protects an immunocompromised mouse from a lethal DENV challenge. Existing antibodies against dengue can enhance subsequent infections via antibody-dependent enhancement. Importantly our vaccine only induced serotype specific immune responses and did not induce ADE.

Golgi network and secreted from the cell. Administration of the DENV1 prM/E mRNA-LNP vaccine elicited neutralizing antibody titers and antiviral specific T cells in wild-type C57BL/6J 115 mice and conferred protection in DENV permissive immunocompromised AG129 mice.

Importantly the mRNA-LNP vaccine induced serotype specific immunity with low levels of ADE.

We designed a construct encoding for the wild-type nucleotide sequence of prM and E proteins 120 from dengue serotype 1 (DENV1) strain 16007 downstream of a Japanese encephalitis virus 121 (JEV) signal peptide. The coding sequence was flanked by a 5' untranslated region (UTR) 122 previously utilized in other mRNA vaccines(23) and the 3' UTR from the human hemoglobin 123 subunit alpha 1 mRNA (HBA1) ( Figure 1A ). The 5' and 3' UTRs contribute to translation 124 regulation and mRNA stability essential for optimum protein expression. We in vitro transcribed 125 mRNA from a T7 RNA polymerase promoter site upstream of the 5' UTR. A 5' cap-1 structure 126 and a 3' poly-A tail were enzymatically added to produce fully mature messenger RNA that 127 resembles host mRNA. We also generated a separate construct (FL) containing the amino 

In vitro synthesized mRNA was transfected into 293T cells followed by collection of cell lysate 133 and supernatant. We performed immunoblots with the monoclonal antibodies 1A1D-2 and 4G2.

1A1D-2 is specific for domain III of the E protein(32-34) and 4G2 binds to the fusion-loop 

The DENV1 prM/E mRNA vaccine elicited both antiviral antibodies and antiviral T cell response.

We hypothesized that the antiviral antibodies are sufficient to protect against a lethal challenge.

To address this hypothesis, we adoptively transferred pooled serum from WT vaccinated mice 252 into AG129 mice. As controls, a second group of mice received pooled serum from naïve mice 253 and a third group of mice received PBS. One day after adoptive transfer, mice were challenged 254 with 10 6 FFU DENV1 Western Pacific strain and monitored for 40 days post infection ( Figure 6 ).

Seven out of 8 mice that received serum from the vaccinated mice were protected against 256 lethality. Six out of seven mice that received naïve serum lost weight and succumbed to viral 

In humans, CD4 + and CD8 + T cells predominantly target capsid and NS3, respectively, following 1.8%

Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a 575 Live-Attenuated Tetravalent Dengue Vaccine Candidate

Dengue-specific subviral nanoparticles: design, creation and characterization

Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses 582 to All Four Viral Serotypes

A tetravalent virus-like particle vaccine designed to 586 display domain III of dengue envelope proteins induces multi-serotype neutralizing 587 antibodies in mice and macaques which confer protection against antibody dependent 588 enhancement in AG129 mice

Virus-like particles displaying envelope 590 domain III of dengue virus type 2 induce virus-specific antibody response in mice

Phase 1 Randomized Study 594 of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United 595 States

Safety and 598 Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-599

Based Adjuvant in a Phase 1 Clinical Trial

Development of dengue DNA vaccines

Dengue envelope-based 604 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-605 lacking, domain III-directed tetravalent neutralising antibodies in mice

Dengue-2 virus-like particle (VLP) based vaccine 607 elicits the highest titers of neutralizing antibodies when produced at reduced 608 temperature

Epitope resurfacing on 611 dengue virus-like particle vaccine preparation to induce broad neutralizing antibody

Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus 615 envelope

Modified mRNA Vaccines Protect 618 against Zika Virus Infection

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center 630 B cell responses

Unmodified mRNA in LNPs constitutes a 633 competitive technology for prophylactic vaccines

Nanoparticles versus Dendritic Cells as Vehicles to 635 Deliver mRNA Encoding Multiple Epitopes for Immunotherapy

Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus 640 Macaques

Sculpting 642 humoral immunity through dengue vaccination to enhance protective immunity

Mutational Evidence for an 645 Internal Fusion Peptide in Flavivirus Envelope Protein E

An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine 648 Has Implications for Flavivirus Vaccine Design

Binding of a neutralizing antibody to dengue virus alters the arrangement of surface 652 glycoproteins

Specific Neutralizing Antibodies against Domain III of Dengue Virus Type 2 Envelope 656 Protein Recognize Adjacent Epitopes

Monoclonal Antibody Mapping of the Envelope 658 Glycoprotein of the Dengue 2 Virus

Synthesis and secretion of 660 recombinant tick-borne encephalitis virus protein E in soluble and particulate form

Dengue virus-like particles: construction and 663 application

Skeletal muscle signal peptide optimization for 665 enhancing propeptide or cytokine secretion

667 Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with 668 increased translational capacity and biological stability

Generating the optimal mRNA for 671 therapy: HPLC purification eliminates immune activation and improves translation of 672 nucleoside-modified, protein-encoding mRNA

Lethal Antibody Enhancement of Dengue Disease in Mice Is 675 Prevented by Fc Modification

Mouse Models to Study Dengue Virus Immunology and 677 Pathogenesis

Mouse models of dengue virus 679 infection for vaccine testing

Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines 683 in Rabbits and Rhesus Macaques

An mRNA Vaccine against 689 SARS-CoV-2 -Preliminary Report

Jansen 694 KU. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. 7830

701 Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

An 704 mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections

Modified mRNA-LNP Vaccines Confer Protection against 707 Experimental DENV-2 Infection in Mice

Dissecting Antibodies Induced by a Chimeric Yellow Fever-710

Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-711 Exposed Individuals

Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and 716 Adolescents

Robust and balanced immune responses 720 to all 4 dengue virus serotypes following administration of a single dose of a live 721 attenuated tetravalent dengue vaccine to healthy, flavivirus-naive adults

Nucleofection induces transient eIF2α 724 phosphorylation by GCN2 and PERK

Human T Cell Response to Dengue Virus 726 Infection

A 729 Modified mRNA Vaccine Targeting Immunodominant NS Epitopes Protects Against Dengue 730 Virus Infection in HLA Class I Transgenic Mice

Manipulation of immunodominant dengue virus E 732 protein epitopes reduces potential antibody-dependent enhancement

Figure 1: DENV prM/E Vaccine Design and Viral Protein Expression

A) Schematic of the DENV genome and engineered mRNA construct. An mRNA encoding for 739 the prM and ENV viral proteins was engineered with N-terminal signal peptide sequence, 5' and 740 3' untranslated regions (UTR) flanking the coding sequence

B) 293T cells were transfected with the in vitro transcribed mRNA 743 encoding for the wild-type sequence (WT), or a mutant version with amino acid substitutions in 744 the fusion-loop epitope (ΔFL). Lysate was analyzed by western blot with the domain III specific 745 1A1D-2 monoclonal antibody and the fusion-loop specific 4G2 monoclonal antibody

Supernatant from transfected cells was purified and concentrated through ultracentrifugation 747 and analyzed for VLPs by western blots with the 1A1D-2 monoclonal antibody or anti-GAPDH

Unpurified cell lysate from WT mRNA transfected cells is included as a control. Shown are 749 representative blots. D) Electron microscopy image of VLPs from purified supernatant of 750 transfected 293T cells showing homogenous shape and size of approximately 30nm

Figure 2: Optimization of Signal Peptide and LNP Delivery

A) Constructs were engineered with alternative signal peptides and in vitro transcribed mRNA 754 was transfected into differentiated murine muscle myoblast C2C12 cells. Cell lysate was 755 analyzed by western blot with 1A1D-2 monoclonal antibody or anti-GAPDH antibodies

Supernatant of transfected C2C12 cells was analyzed by dot blot with 1A1D-2. C) In vitro 757 synthesized WT or ΔFL mRNA was encapsulated into a lipid nanoparticle and administered to 758 C2C12 cells. Lysate was analyzed by western blot with 1A1D-2 antibody

Figure 3: DENV1 prM/E mRNA Vaccines Induce Neutralizing Antibody Response 762 DENV1 prM/E mRNA-LNP vaccines were administered into 10 week-old C57Bl/6 mice. A.) Mice 763 were administered 10ug of mRNA vaccine in a three-shot schedule and serum collected at the 764 indicated time points. B) Serial dilutions of serum from vaccinated mice were analyzed for 765 neutralization activity with a FRNT assay against DENV1 strain 16007. Neutralization curves at 766 each timepoint are shown for WT vaccine recipients

Mice were administered a 768 high (10ug) or low (3ug) dose of the mRNA vaccines, or vaccine encoding for GFP. A separate 769 group of mice were infected with wild-type DENV1 following the same schedule. D) Antiviral IgG 770 titers were determined by ELISA assays and the endpoint dilution titer calculated. E) Serum was 771 analyzed by FRNT assays and the normalized percentage infection of each group is plotted as 772 the mean +/-SEM for each serum dilution. N=5 mice per groups of mice infected with virus or 773 receiving 3 ug vaccine doses

N=15 for mice receiving 10 ug doses of the WT vaccine. F) EC50 values of 775 the neutralization curves from individual mice are shown. Statistical significance of each group 776 compared to the GFP control was determined via unpaired T-test. P-values <0.01 are signified 777 by ** and <0.001 by ***

Cells 780 DENV1 prM/E mRNA-LNP vaccines were administered into 10 week-old C57Bl/6 mice in a 781 three-shot vaccination schedule. Spleens were harvested after the final vaccination dose (day 782 56) and stimulated with an overlapping peptide

Stimulated cells were stained for the intracellular cytokine IFN and 784 analyzed by flow cytometry. Plotted is the IFNγ + T cells as a percentage of total CD8+ T cells 785 (A) or CD4+ T cells (B). N = 5 mice in the WT and ΔFL vaccinated groups

A